Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Perioperative SOX vs Postoperative SOX or XELOX in Gastric Cancer
NCT01534546Phase 3Unknown
- Sponsor
- Peking University
- Start
- Mar 2012
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur in gastric adenocarcinoma (3 arms), sponsored by Peking University. Primary endpoint: Disease Free Survival at 3 years. Status: unknown.
02
Drugs
tegafur
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT01534546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534546.